Prophylaxis of invasive fungal infections, including both yeasts & moulds, in patients ≥13 yr, who are at high risk of developing these infections, eg, patients w/ prolonged neutropenia or hematopoietic stem cell transplant (HSCT). Invasive aspergillosis in patients ≥13 yr w/ disease refractory to amphotericin B, itraconazole or voriconazole, or intolerant to these drugs. Esophageal candidiasis or candidemia in patients ≥13 yr w/ disease refractory to amphotericin B, fluconazole or itraconazole, or in patients who are intolerant of these drugs. Fusariosis, zygomycosis, cryptococcosis, chromoblastomycosis & mycetoma in patients ≥13 yr w/ disease refractory to other therapy, or patients who are intolerant of other therapy. Coccidioidomycosis.
Prophylaxis of invasive fungal infections Loading dose: 300 mg bid on 1st day, then 300 mg once daily thereafter. Patient w/ acute myelogenous leukemia or myelodysplastic syndromes Start several days before anticipated onset of neutropenia & continue for 7 days after neutrophil count rises >500 cells/mm3. Refractory invasive fungal infections/intolerant patient w/ invasive fungal infections, & coccidioidomycosis; oesophageal candidiasis Loading dose: 300 mg bid on the 1st day, then 300 mg once daily thereafter.
Hypersensitivity to other azoles. Monitor K, Mg or Ca levels & correct as necessary prior to & during therapy. Concomitant use w/ QTc interval prolonging drugs; vincristine; venetoclax. Hepatic toxicity & impairment. Pregnancy & lactation. Childn <13 yr.
Sign Out
